BioTime CEO Dr. Michael West to Present at Scale-Up and Manufacturing of Cell-Based Therapies II Conference

  BioTime CEO Dr. Michael West to Present at Scale-Up and Manufacturing of
  Cell-Based Therapies II Conference

Scale-Up and Manufacturing of Cell-Based Therapies II

Business Wire

ALAMEDA, Calif. -- January 18, 2013

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and
markets products in the field of regenerative medicine, today announced that
Chief Executive Officer Michael D. West, PhD will present at the Scale-Up and
Manufacturing of Cell-Based Therapies II conference in San Diego, California
on Monday, January 21, 2013. Dr. West’s presentation titled “hES-Derived
Clonal Embryonic Progenitor Cell Lines: A Novel Point of Scalability” is
scheduled for 4:30 pm PST. Dr. West will describe BioTime’s novel and
proprietary PureStem^TM technology which allows the industrial scale-up of
over 200 different human cell types in a highly purified state from human
embryonic stem cells. In addition, Dr. West will present new data recently
generated using the technology. The presentation will be made available on
BioTime's website at

The second annual conference on Scale-Up and Manufacturing of Cell-Based
Therapies is scheduled for January 21-23, 2013. It is sponsored by Engineering
Conferences International, a not-for-profit global engineering conferences
program, originally established in 1962, that provides opportunities for the
exploration of problems and issues of concern to engineers and scientists from
many disciplines. This conference will focus on process development, scale-up,
and manufacturing of cell-based therapies and will bring academicians,
clinicians, industry leaders, and regulators from all over the world together
to discuss the most critical scientific and engineering challenges in this

Pluripotent stem cells such as human embryonic stem and induced pluripotent
stem cells have attracted a great deal of attention in the research community
and pharmaceutical industry as a potential means of manufacturing a wide array
of novel cell-based therapies where cells, as opposed to drugs, are introduced
into the body to regenerate tissue function. However, since these new and
powerful stem cells become all of the cell types in the human body, methods to
reliably scale up only particular and desired cell types from the stem cells
without contamination from other undesired cell types are of significant
interest. BioTime’s solution is a proprietary PureStem^TM technology that
generates monoclonal lines of over 200 defined human embryonic progenitor cell
types from human embryonic stem cells. This technology allows desired cell
types such as cartilage, bone, tendon, vascular cells, and many other cell
types to be manufactured on an industrial scale while maintaining a high
degree of purity and certainty of cellular identity.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company
focused on regenerative medicine and blood plasma volume expanders. Its broad
platform of stem cell technologies is enhanced through subsidiaries focused on
specific fields of application. BioTime develops and markets research products
in the fields of stem cells and regenerative medicine, including a wide array
of proprietary PureStem™ cell lines, HyStem^® hydrogels, culture media, and
differentiation kits. BioTime is developing Renevia™ (formerly known as
HyStem^®-Rx), a biocompatible, implantable hyaluronan and collagen-based
matrix for cell delivery in human clinical applications. BioTime's therapeutic
product development strategy is pursued through subsidiaries that focus on
specific organ systems and related diseases for which there is a high unmet
medical need. BioTime's majority owned subsidiary Cell Cure Neurosciences Ltd.
is developing therapeutic products derived from stem cells for the treatment
of retinal and neural degenerative diseases. BioTime's subsidiary OrthoCyte
Corporation is developing therapeutic applications of stem cells to treat
orthopedic diseases and injuries. Another subsidiary, OncoCyte Corporation,
focuses on the diagnostic and therapeutic applications of stem cell technology
in cancer, including the diagnostic product PanC-Dx™ currently being developed
for the detection of cancer in blood samples. ReCyte Therapeutics, Inc. is
developing applications of BioTime's proprietary induced pluripotent stem cell
technology to reverse the developmental aging of human cells to treat
cardiovascular and blood cell diseases. BioTime's subsidiary LifeMap Sciences,
Inc. markets GeneCards^®, the leading human gene database, and is developing
an integrated database suite to complement GeneCards^® that will also include
the LifeMap Discovery™ database of embryonic development, stem cell research
and regenerative medicine, and MalaCards, the human disease database. LifeMap
will also market BioTime research products. BioTime Acquisition Corporation
(“BAC”) is a subsidiary being used to acquire the stem cell assets of Geron
Corporation, including patents and other intellectual property, biological
materials, reagents and equipment. BioTime's lead product, Hextend^®, is a
blood plasma volume expander manufactured and distributed in the U.S. by
Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under exclusive
licensing agreements. Additional information about BioTime can be found on the
web at

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future
growth in research, technology, clinical development, and potential
opportunities for BioTime and its subsidiaries, along with other statements
about the future expectations, beliefs, goals, plans, or prospects expressed
by management constitute forward-looking statements. Any statements that are
not historical fact (including, but not limited to statements that contain
words such as "will," "believes," "plans," "anticipates," "expects,"
"estimates") should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including, without
limitation, risks inherent in the development and/or commercialization of
potential products, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital, and
maintenance of intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking statements
and as such should be evaluated together with the many uncertainties that
affect the business of BioTime and its subsidiaries, particularly those
mentioned in the cautionary statements found in BioTime's Securities and
Exchange Commission filings. BioTime disclaims any intent or obligation to
update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list:


BioTime, Inc.
Peter Garcia, 510-521-3390, ext 367
Chief Financial Officer
Judith Segall, 510-521-3390, ext 301
Press spacebar to pause and continue. Press esc to stop.